Literature DB >> 16079531

Comparison of the metabolism of baicalin in rats orally administered with Radix scutellariae extract and Shuang-Huang-Lian extract.

Nian-Ping Feng1, Bin Di, Wen-Ying Liu.   

Abstract

Shuang-Huang-Lian (SHL) is a traditional Chinese formula containing Flos lonicerae, Radix scutellariae (RS) and Fructus forsythiae, and is commonly used for treating acute upper respiratory tract infection, acute bronchitis and light pneumonia. The aim of the present study is to compare the metabolites of baicalin in rats when orally administered with SHL and Radix scutellariae, and try to explore the principle of SHL compatibility. By using LC-MS(n) and HPLC-DAD, the metabolites of baicalin were analyzed from bile, urine and feces of rats dosed with SHL and RS. Our results showed significant difference of baicalin metabolism between RS and SHL. However, baicalein was found to be the main metabolites of baicalin in intestinal tract after oral administration of RS and SHL, glucuronide, glucoside and methylated products were also found in rat urine after administration of either RS or SHL. Meanwhile, several sulphates were found in rat urine after RS administration, but not found after SHL. Among the metabolites of the SHL, potentially there existed a isomerized baicalin and methylated product: 5,7-dihydroxy-6-methoxyisoflavone-7-O-beta-glucopyranuronoside, but without unidentified metabolite M3. Baicalein-6-O-beta-glucopyranuronoside-7-O-beta-glucopyranuronoside and baicalein-6-O-beta-glucose-7-O-beta-glucopyranuronoside were first reported by this study. The major metabolites of baicalin of RS and SHL in rat bile were the same, including baicalin-6-O-beta-glucopyranuronoside-7-O-beta-glucopyranuronoside, baicalin-6-beta-glucopyranuronoside and 6-O-methyl-baicalin-7-O-beta-glucopyranuronoside. Moreover, baicalein-6-O-beta-glucose-7-O-beta-glucopyranuronoside was also first found in rat bile by this study. Although baicalin-6-O-sulfate-7-O-beta-glucopyranuronoside was found in rat bile after RS administration, no sulphated products were found after oral administration of SHL. These differences of baicalin metabolism between RS and SHL indicated that compatibility of medicines could result in the differences of metabolites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079531     DOI: 10.1248/cpb.53.978

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  5 in total

1.  Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.

Authors:  Han-Lin Gong; Wen-Fu Tang; Jia Wang; Guang-Yuan Chen; Xi Huang
Journal:  Chin J Integr Med       Date:  2012-08-31       Impact factor: 1.978

2.  Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

Authors:  Wei Zhang; Muhammad W Saif; Ginger E Dutschman; Xin Li; Wing Lam; Scott Bussom; Zaoli Jiang; Min Ye; Edward Chu; Yung-Chi Cheng
Journal:  J Chromatogr A       Date:  2010-07-21       Impact factor: 4.759

3.  The metabolism of baicalin in rat and the biological activities of the metabolites.

Authors:  Yi Wang; Jingyu Yang; Xian Li; Jinhui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-13       Impact factor: 2.629

4.  BA-j as a novel CDK1 inhibitor selectively induces apoptosis in cancer cells by regulating ROS.

Authors:  Shixuan Zhang; Yongming Bao; Xiulan Ju; Kangjian Li; Haiyan Shang; Lisha Ha; Yuan Qian; Liang Zou; Xiaodan Sun; Jing Li; Qianru Wang; Qingyu Fan
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

5.  Inhibitory Effect of Sargassum fusiforme and Its Components on Replication of Respiratory Syncytial Virus In Vitro and In Vivo.

Authors:  Kiramage Chathuranga; Asela Weerawardhana; Niranjan Dodantenna; Lakmal Ranathunga; Won-Kyung Cho; Jin Yeul Ma; Jong-Soo Lee
Journal:  Viruses       Date:  2021-03-25       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.